knowledge -WSS

knowledge

author：entertainment 2025-09-27 22:56:30 - browse：62

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Study fuels hope CAR

WSS

TikTok cracks down on users posting about weight loss drugs

Why some people catch Covid but never get sick

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Celebrate National Dole Whip Day for 3 days this week at Disney

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

'Vaccine

hotspot

knowledge

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare isn't yet testing food as medicine

DIEP, the 'gold standard' of breast reconstruction, is under threat

5 ways to address the shortage of health care workers

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage isn’t working — for anyone

Sports medicine is finally prioritizing gender equality

Doctor of U.S. President Joe Biden says he is fit for duty

United colonoscopy coverage change 'may cost lives,' doctors say

'Reaching a detente': STAT's Helen Branswell on covering Covid

leisure time

NEJM study measures Covid brain fog, impact on IQ

Researchers separate signal from noise in heart wearable data

NEJM study measures Covid brain fog, impact on IQ

Researchers separate signal from noise in heart wearable data

The kidney, in all its complexity, is captured in a new atlas

Cholera vaccine supplies dangerously low, outbreaks surging

hotspot

leisure time

knowledge

focus